Rivaroxaban Impurity 17 - Request Quote
Rivaroxaban Impurity 17
| SZ CAT No: | SZ-R017040 |
| CAS No | NA |
| Mol.F. | C28H31N5O8 |
| Mol.Wt. | 565.6 |
| Inv. Status | In Stock |
| Shipping Condition | Room Temperature |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Rivaroxaban Impurity 17 is chemically 4-(4-((((S)-2-oxo-3-(((S)-2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)oxazolidin-5-yl)methyl)amino)phenyl)morpholin-3-one. Rivaroxaban Impurity 17 is supplied with detailed characterization data compliant with regulatory guideline. Rivaroxaban Impurity 17 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Rivaroxaban.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
buy high quality Rivaroxaban Impurity 17
Purchase Rivaroxaban Impurity 17
Rivaroxaban Impurity 17 suppliers
Rivaroxaban Impurity 17 manufacturers
Rivaroxaban Impurity 17 price
Order Rivaroxaban Impurity 17
Enquire Rivaroxaban Impurity 17
Rivaroxaban Impurity 17 cost
Rivaroxaban Impurity 17 Supplier
Rivaroxaban Impurity 17 Distributor
Rivaroxaban Impurity 17 for Method Validation
Rivaroxaban Reference Standard
Rivaroxaban Impurity 17 for ANDA Filing
Rivaroxaban Impurity 17 for Forced Degradation Studies
Rivaroxaban Impurity 17 Identification Standards
Rivaroxaban Impurity 17 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


